DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ASTRAZENECA PHARMA IND LT (ASTRAZEN) share price today?

ASTRAZENECA PHARMA IND LT (ASTRAZEN) is trading at ₹8,023.5 on the NSE, down 0.77% on the day. Source: DocStoX.

What is the PE ratio of ASTRAZENECA PHARMA IND LT?

ASTRAZENECA PHARMA IND LT has a price-to-earnings (PE) ratio of 173.3 in the Healthcare sector.

What is the market capitalisation of ASTRAZENECA PHARMA IND LT?

ASTRAZENECA PHARMA IND LT has a market capitalisation of approximately ₹20,110 crore.

ASTRAZENECA PHARMA IND LT

ASTRAZEN·NSE·Healthcare

₹8,023.50▼ -62.50 (-0.77%)

Healthcare · Pharmaceuticals

A steady, established business

Day₹7933.00

₹8170.00

52W₹7552

₹985021%

Open

₹8070.00

High

₹8170.00

Low

₹7933.00

Prev Close

₹8086.00

Volume

8.9K

VWAP

₹8056.90

Snapshot

Key fundamentals

Market Cap

₹20,110 Cr

P/E Ratio

173.29Expensive

P/B Ratio

23.66

EPS

₹46.30

Book Value

₹349.12

ROE

15.02%Strong

ROCE

33.00%Efficient

Dividend Yield

0.39%

Debt / Equity

0.13Low

Face Value

₹2.00

52W High

₹9849.50

52W Low

₹7551.50

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatHigh uncertainty

Fair value estimate

₹441

▼ 94.5%downside

Trading at ₹8,024 — 95% above our estimate

BearFair valueBull

₹375₹441₹603

/100

Business quality — Watch the fundamentals

Growth 0Profitability 38Efficiency 50Valuation 47

Plain English

Our view

A steady, established business
Low debt relative to equity
Expensive — trades at 173× earnings

Strengths

Low debt relative to equity
Capital is working hard (ROCE 33%)
Promoters hold a controlling stake

Risks

Expensive — trades at 173× earnings
Fundamental red flags (Piotroski 3/9)

How we got there

Fair value methods

Residual income

15% ROE fading to 12% over ~10 yrs, on ₹349 book

₹396

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹603

Analyst target

No analyst coverage

—

Blended fair value₹441

What the numbers say

Investment thesis

Bull case

Low debt relative to equity
Capital is working hard (ROCE 33%)
Promoters hold a controlling stake

Bear case

Expensive — trades at 173× earnings
Fundamental red flags (Piotroski 3/9)

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

173.3Expensive

Below 15× is value territory; above 35× prices in strong growth

ROE

15.0%Strong

Above 15% is considered healthy for Indian equities

ROCE

33.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.13Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹20,110 Cr

P/B

23.66

EPS

₹46.30

Div Yield

0.39%

What changed

Recent changes

Domestic institutions+0.2% stake last quarter

What matters

News impact

Overview

Valuation

Expensive

P/E 173.3×

Growth

Strong

+31% rev CAGR

Profitability

Healthy

15.0% ROE

Financial health

Rock solid

D/E 0.13

Momentum

N/A

No technicals

Today

Trading activity

Delivery %49.7%

Turnover₹718.19L Cr

Trades1,900

VWAP₹8056.90

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+31.4%

+22.8%

10Y

+15.0%

Profit

+23.7%

+15.1%

10Y

+43.7%

EPS

—

10Y

—

Profile

Pros

Company is expected to give good quarter
Company has been maintaining a healthy dividend payout of 51.4%

Watch-outs

Cons

Stock is trading at 23.2 times its book value

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 31 Mar 2026

Domestic institutions added 0.24 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

75%

Promoter

Promoters

75.0%0.00

Public

16.4%-0.31

FII / FPI

2.8%+0.07

DII

5.8%+0.24

Total shareholders

29,007-2,544 QoQ

Quarterly trend

Ownership over time

Q4 FY26

Promoter75.00%

FII2.78%

DII5.79%

Public16.42%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions

AstraZeneca Pharma India Ltd is engaged in the business of manufacture, distribution and marketing of pharmaceutical products.[1]